Moomoo AIのまとめ
On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
On September 30, 2024, Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating a change in their holdings of Adial Pharmaceuticals, Inc. common stock. The filing revealed that both Armistice Capital and Boyd individually have shared voting and dispositive power over 336,310 shares of Adial Pharmaceuticals, which represents 4.99% of the company's class of common stock. The filing was made under Rule 13d-1(b), which applies to certain institutional investment managers. The shares are held by the Master Fund, which is managed by Armistice Capital, and Steven Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities held by the Master Fund. The Master Fund disclaims beneficial ownership of the securities due to its Investment Management Agreement with Armistice Capital. The filing also certifies that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Adial Pharmaceuticals.
2024年9月30日、Armistice Capital、LLCとSteven Boydは、米国証券取引委員会に修正されたスケジュール13G/Aを提出し、Adial Pharmaceuticals, Inc.の普通株式保有に変更があったことを示しました。提出された文書によると、Armistice CapitalとBoydは個別に336,310株のAdial Pharmaceuticalsの株式について共同で投票権と処分権を持っており、これは同社の普通株式の4.99%を表しています。この提出は、特定の機関投資家に適用されるルール13d-1(b)の下で行われました。これらの株式は、Armistic...すべて展開
2024年9月30日、Armistice Capital、LLCとSteven Boydは、米国証券取引委員会に修正されたスケジュール13G/Aを提出し、Adial Pharmaceuticals, Inc.の普通株式保有に変更があったことを示しました。提出された文書によると、Armistice CapitalとBoydは個別に336,310株のAdial Pharmaceuticalsの株式について共同で投票権と処分権を持っており、これは同社の普通株式の4.99%を表しています。この提出は、特定の機関投資家に適用されるルール13d-1(b)の下で行われました。これらの株式は、Armistice Capitalが運用するマスターファンドが保有しており、Armistice Capitalの運営メンバーであるSteven Boydは、マスターファンドが保有する証券の恩恵を受けるように見なされる可能性があります。マスターファンドはArmistice Capitalとの運用管理契約により、証券の恩恵を受けることを放棄しています。提出された文書は、これらの証券がビジネスの通常の過程で取得されたものであり、Adial Pharmaceuticalsの支配権を変更または影響を与える目的でではなく取得されたことを証明しています。
役に立った
役に立たない
この開示の添付ファイルは以下です：
